54gene is an African genomics company building the world’s largest pan-African biobank.
54gene is on a mission to improve our understanding of the human genome in order to advance the quality of healthcare worldwide.
54gene was founded in 2019 in Nigeria by Dr. Abasi Ene-Obong. The company is based in Lekki, Lagos, Nigeria and San Francisco, California.
54gene is targeting multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease.
54gene provides genetic testing and molecular diagnostics services to patients and physicians in order to expand access to precision medicine in Africa.
54gene is partnering with hospitals and research institutions in African countries; and with pharmaceutical and biotechnology companies to address the challenge of limited diverse genomics data, which may hold the key to medical discoveries and new healthcare solutions.
54gene is backed by investors including Y Combinator, Adjuvant Capital, The Bill and Melinda Gates Foundation, Novartis, Fifty Years Ventures, Better Ventures, KdT Ventures and others. The company raised $15M in a Series A round on Apr 14, 2020. This brings 54gene's total funding to $19.5M to date.